Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for IDEAYA Biosciences, Inc. (IDYA : NSDQ)

• Company Description    IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences Inc. is based in South San Francisco, United States. Number of Employees: 131

• Price / Volume Information    Yesterday's Closing Price: $24.61 Daily Weekly Monthly 20 Day Moving Average: 1,194,808 shares Shares Outstanding: 87.64 (millions) Market Capitalization: $2,156.92 (millions) Beta: 0.12 52 Week High: $37.80 52 Week Low: $13.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.98% -0.79% 12 Week 12.58% 2.26% Year To Date -4.24% -13.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5000 SHORELINE COURT SUITE 300 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-443-6209 fax: - investor@ideayabio.com http://www.ideayabio.com

• General Corporate Information    Officers Yujiro Hata - Chief Executive Officer;President Terry Rosen - Chairman of the Board of Directors Andres Ruiz Briseno - Senior Vice President and Head of Finance and Inve Garret Hampton - Director Susan L. Kelley - Director Peer Information IDEAYA Biosciences, Inc. (CORR.) IDEAYA Biosciences, Inc. (RSPI) IDEAYA Biosciences, Inc. (CGXP) IDEAYA Biosciences, Inc. (BGEN) IDEAYA Biosciences, Inc. (GTBP) IDEAYA Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45166A102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/03/25 Share - Related Items Shares Outstanding: 87.64 Most Recent Split Date: (:1) Beta: 0.12 Market Capitalization: $2,156.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.79 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.25 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -29.41% vs. Previous Quarter: -7.32% Sales Growth vs. Year Ago Period: 78.43% vs. Previous Quarter: -% ROE 06/30/25 - -31.42 03/31/25 - -29.28 12/31/24 - -26.74 ROA 06/30/25 - -29.45 03/31/25 - -27.68 12/31/24 - -25.54 Current Ratio 06/30/25 - 12.39 03/31/25 - 13.92 12/31/24 - 14.97 Quick Ratio 06/30/25 - 12.39 03/31/25 - 13.92 12/31/24 - 14.97 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - -4,740.03 03/31/25 - -4,386.90 12/31/24 - -3,921.10 Book Value 06/30/25 - 10.96 03/31/25 - 11.69 12/31/24 - 12.25 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©